Objective: It is known that a 32-bp-deleted CCR5 mutant (CCR5-Δ32) plays a critical role in resistance to human immunodeficiency virus type 1 (HIV-1) infection. We became aware of a number of seronegative patients at high risk of HIV-1 infections. Since CCR-Δ32 is not found in Thais, we examined the role of stromal cell-derived factor (SDF) 1-3′A polymorphism in resistance to HIV-1 in seronegative Thai prostitutes at high risk. Methods: We determined CCR5-Δ32 by PCR, SDF1-3′A by RFLP, and plasma SDF-1 level by sandwich ELISA. Results: We did not find any CCR-Δ32 mutant in 432 subjects. In our SDF1-3′A genotyping, we found allelic frequencies of 0.406, 0.199, and 0.289 in HIV-1-seronegative prostitutes at high risk, HIV-1-seropositive patients, and normal blood donors, respectively. There was a significant difference in the allelic frequencies of SDF1-3′A between HIV-1-seronegative prostitutes at high risk and HIV-1-seropositive patients (p < 0.005). Striking differences were seen in homozygotes (SDF1-3A/3A); 20.3% in HIV-1-seronegative patients at high risk compared with 2.5% in HIV-1-seropositive patients. In addition, we showed that the plasma SDF1 level in the HIV-1-seronegative prostitutes at high risk was twice that found in normal blood donors (p = 0.005), and even higher than that of HIV-1-seropositive patients (p = 0.002). Conclusions: The finding is relevant as regards the fact that SDF1-3′A polymorphism induces an increase of SDF1 chemokine production, in which it competes with HIV-1 in binding to CXCR4 receptor, and in turn inhibits HIV-1 infection. The SDF1-3′A-mediated resistant mechanism in Thais differs from that of CCR5-Δ32-mediated resistance in Caucasians. This study provides the first evidence for SDF-3′A polymorphism in resistance to HIV-1 infection in Thais, and may represent the resistant mechanism in the extremely rare CCR5-Δ32 mutant of other ethnic groups such as Africans and Japanese.

Keywords:
Human immunodeficiency virus type 1, SDF1-3′A, CCR5-Δ32, Polymorphism, Resistance
This content is only available via PDF.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.